Eptapirone

Eptapirone

Eptapirone is a potent and highly selective 5-HT1A receptor full agonist of the azapirone chemical class. It is an anxiolytic drug that was first synthesized by Bristol-Myers Squibb in 1986. Eptapirone is structurally related to other azapirones like buspirone and ipsapirone.

Pharmacology

Eptapirone acts as a full agonist at the 5-HT1A receptor, meaning it can produce the maximum response possible from this receptor. This is in contrast to partial agonists, which can only produce a partial response regardless of the drug dosage. The 5-HT1A receptor is a subtype of the 5-HT receptor that binds the neurotransmitter serotonin, and is involved in a variety of functions including mood, anxiety, and cognition.

Clinical Use

Eptapirone has been studied for its potential use in the treatment of anxiety disorders, depression, and other conditions. However, as of 2021, it is not currently approved for medical use in any country.

Chemistry

Eptapirone belongs to the azapirone class of compounds, which are characterized by their pyrimidinylpiperazine and furanopyridine moieties. Other azapirones include buspirone, gepirone, and ipsapirone, all of which also act as 5-HT1A receptor agonists.

See Also

• 5-HT1A receptor
• Azapirone
• Buspirone
• Gepirone
• Ipsapirone

References

<references />

This article is a stub related to pharmacology. You can help WikiMD by expanding it!